autologous T cell therapy
Showing 1 - 25 of >10,000
AML, B-ALL, T-ALL Trial in Memphis (CD123-CAR T, Cyclophosphamide, Fludarabine)
Recruiting
- AML
- +4 more
- CD123-CAR T
- +4 more
-
Memphis, Tennessee
- +1 more
May 10, 2022
Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma Trial in Memphis (Fludarabine, Cyclophosphamide, MESNA)
Recruiting
- Pediatric Solid Tumor
- +15 more
- Fludarabine
- +3 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Jun 30, 2022
ASCT Versus Chemotherapy as First-Line Consolidation Therapy
Completed
- T-cell Lymphoma Adults
- consolidation with ASCT
- (no location specified)
Nov 25, 2023
Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)
Not yet recruiting
- Neuroendocrine Tumor (NET)
- Colorectal Cancer (CRC)
- CHM-2101 CAR-T cells
- (no location specified)
Sep 20, 2023
Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia Trial in Los Angeles (autologous hematopoietic stem
Not yet recruiting
- Hematologic Malignancy
- +5 more
- autologous hematopoietic stem cells added to planned CAR T
-
Los Angeles, CaliforniaCedars-Sinai Medical Center
May 31, 2023
Lymphomas, B-cell Lymphomas Trial in Houston (JV-213, Leukapheresis)
Not yet recruiting
- Lymphomas
- B-cell Lymphomas
- JV-213
- Leukapheresis
-
Houston, TexasThe University of Texas M D Anderson Cancer Center
Mar 6, 2023
Chronic Hepatitis B Trial in Beijing (TCR-T)
Active, not recruiting
- Chronic Hepatitis B
- TCR-T
-
Beijing, ChinaThe Fifth Medical Center of PLA General Hospital
Jun 13, 2023
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited Trial in Zhengzhou (ThisCART19A, Fludarabine Pill, Cyclophosphamide)
Not yet recruiting
- Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
- ThisCART19A
- +3 more
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Nov 28, 2022
Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)
Recruiting
- Non-hodgkin Lymphoma,B Cell
- Autologous CD19-STAR-T cell
- +2 more
-
Beijing, Beijing, China
- +1 more
Nov 21, 2022
Recurrent Glioblastoma Trial in Beijing (Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous
Not yet recruiting
- Recurrent Glioblastoma
- Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.
-
Beijing, Beijing, ChinaBeijing Tiantan Hospital
Oct 10, 2022
T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)
Withdrawn
- T Cell Lymphoma
- Brentuximab Vedotin
-
Kansas City, KansasThe University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022
Not yet recruiting
- Cancer
- Relapsed/Refractory Large B-cell Lymphoma (LBCL)
- Fludarabine (30 mg/m^2)
- +2 more
- (no location specified)
Jul 25, 2023
B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B Lineage Lymphoblastic Lymphoma
- Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
- Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jan 25, 2023
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto
Not yet recruiting
- Multiple Sclerosis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Palo Alto, CaliforniaStanford Multiple Sclerosis Center
Nov 13, 2023
Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,
Recruiting
- Lupus Nephritis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Denver, Colorado
- +1 more
Jul 7, 2023
Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma Trial in Taiyuan (CAR-T Autologous T cell injection)
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- CAR-T Autologous T cell injection
-
Taiyuan, Shanxi, ChinaShanxi Bethune Hospital
Dec 2, 2022
Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,
Not yet recruiting
- Kidney Transplant
- +2 more
- Cyclophosphamide
- +3 more
-
Boston, Massachusetts
- +2 more
Sep 20, 2023
T-cell Non-Hodgkin Lymphoma Trial in Boston (Cyclophosphamide, Doxorubicin, Vincristine)
Terminated
- T-cell Non-Hodgkin Lymphoma
- Cyclophosphamide
- +12 more
-
Boston, Massachusetts
- +1 more
Jan 26, 2023
Acute Myeloid Leukemia (AML), B-cell Non-Hodgkin's Lymphoma (B-NHL), Multiple Myeloma (MM) Trial in Shanghai (Autologous CAR-T
Recruiting
- Acute Myeloid Leukemia (AML)
- +4 more
- Autologous CAR-T cells
- +2 more
-
Shanghai, Shanghai, ChinaShanghai Pudong Hospital, Fudan University Affiliated Pudong Med
Aug 22, 2022
Head Neck Cancer, Relapse, Recurrent Trial in Chapel Hill (Cyclophosphamide, Fludarabine, Cell Therapy)
Not yet recruiting
- Head and Neck Cancer
- +3 more
- Cyclophosphamide
- +2 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Oct 18, 2023
B Acute Lymphoblastic Leukemia Trial in Duarte (drug, procedure, other)
Not yet recruiting
- B Acute Lymphoblastic Leukemia
- Autologous Anti-CD19 CAR-expressing T Lymphocytes
- +6 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 30, 2023
Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,
Not yet recruiting
- Prostate Carcinoma
- +3 more
- Bendamustine
- +12 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 17, 2023
Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma Trial in Seattle
Terminated
- Hematopoietic and Lymphoid Cell Neoplasm
- +12 more
- Laboratory Biomarker Analysis
- ROR1 CAR-specific Autologous T-Lymphocytes
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 11, 2022
Liver Cell Carcinoma Trial in Houston (CATCH T cells, Cytoxan, Fludara)
Recruiting
- Liver Cell Carcinoma
- +7 more
- CATCH T cells
- +2 more
-
Houston, TexasHouston Methodist Hospital
Dec 19, 2022